Palomar (NASDAQ:PLMR) Announces Earnings Results, Beats Expectations By $0.17 EPS

Palomar (NASDAQ:PLMR) posted its quarterly earnings results on Tuesday. The company reported $2.36 EPS for the quarter, topping the consensus estimate of $2.19 by $0.17, FiscalAI reports. Palomar had a net margin of 20.11% and a return on equity of 22.62%. The firm had revenue of $314.42 million for the quarter, compared to the consensus estimate of $621.52 million. During the same period last year, the firm posted $1.76 earnings per share.

Palomar Price Performance

PLMR stock traded down $0.91 during midday trading on Wednesday, hitting $135.20. The company’s stock had a trading volume of 140,467 shares, compared to its average volume of 269,339. The firm has a market capitalization of $3.58 billion, a price-to-earnings ratio of 18.83 and a beta of 0.40. Palomar has a 12 month low of $100.81 and a 12 month high of $147.62. The company has a quick ratio of 0.49, a current ratio of 0.49 and a debt-to-equity ratio of 0.31. The company has a 50 day moving average of $125.19 and a two-hundred day moving average of $123.58.

Palomar Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 2nd. Stockholders of record on Wednesday, August 19th will be given a $0.45 dividend. This represents a $1.80 annualized dividend and a dividend yield of 1.3%. The ex-dividend date is Wednesday, August 19th.

Analyst Ratings Changes

PLMR has been the topic of a number of recent research reports. Weiss Ratings raised shares of Palomar from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, June 18th. Keefe, Bruyette & Woods raised their target price on shares of Palomar from $162.00 to $166.00 and gave the company an “outperform” rating in a research note on Wednesday, July 8th. Zacks Research lowered shares of Palomar from a “strong-buy” rating to a “hold” rating in a report on Friday, May 15th. Piper Sandler raised their price objective on Palomar from $132.00 to $165.00 and gave the company an “overweight” rating in a research report on Wednesday, July 15th. Finally, Evercore set a $152.00 target price on Palomar in a report on Friday, July 10th. Four equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, Palomar presently has an average rating of “Moderate Buy” and a consensus target price of $162.50.

More Palomar News

Here are the key news stories impacting Palomar this week:

• Positive Sentiment: Palomar reported second-quarter 2026 EPS of $2.36, beating the $2.19 consensus estimate and increasing from $1.76 a year earlier. The company also posted a 20.11% net margin and 22.62% return on equity. Palomar Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: The insurer declared a quarterly dividend of $0.45 per share, payable September 2 to shareholders of record August 19. The dividend equates to $1.80 annually and a yield of approximately 1.3%. Palomar dividend announcement
• Neutral Sentiment: Zacks Research maintained a “Hold” rating while making modestly mixed revisions: FY2027 EPS rose to $9.70 from $9.66 and Q1 2027 estimates increased to $2.22 from $2.18, but Q1 2028 EPS fell to $3.08 from $3.12 and Q2 2028 EPS declined to $2.12 from $2.26. Palomar analyst estimate revisions
• Negative Sentiment: Reported revenue of $314.42 million was substantially below the approximately $621.5 million analyst estimate cited in the earnings reports. That top-line miss may have overshadowed the EPS beat and raised concerns about growth, despite strong profitability. Palomar Q2 earnings metrics
• Negative Sentiment: Zacks also reduced its FY2028 EPS forecast to $10.45 from $10.62, signaling softer longer-term earnings expectations. Palomar FY2028 estimate reduction

Insider Buying and Selling at Palomar

In other news, insider Timothy Carter sold 480 shares of the stock in a transaction on Sunday, June 28th. The shares were sold at an average price of $124.29, for a total value of $59,659.20. Following the sale, the insider owned 1,670 shares of the company’s stock, valued at approximately $207,564.30. This represents a 22.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Jon Christianson sold 6,863 shares of Palomar stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $139.50, for a total transaction of $957,388.50. Following the transaction, the president directly owned 66,478 shares of the company’s stock, valued at approximately $9,273,681. This represents a 9.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 22,050 shares of company stock valued at $2,875,050. Corporate insiders own 3.70% of the company’s stock.

Institutional Trading of Palomar

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Kestra Advisory Services LLC purchased a new stake in shares of Palomar in the fourth quarter valued at approximately $33,000. NewEdge Advisors LLC purchased a new position in Palomar in the 1st quarter worth $66,000. Advisory Services Network LLC acquired a new stake in Palomar during the 3rd quarter worth about $57,000. Smartleaf Asset Management LLC grew its stake in Palomar by 25.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 672 shares of the company’s stock valued at $91,000 after purchasing an additional 137 shares during the last quarter. Finally, iSAM Funds UK Ltd acquired a new position in shares of Palomar in the third quarter valued at about $81,000. Hedge funds and other institutional investors own 90.25% of the company’s stock.

Palomar Company Profile

Palomar Holdings, Inc (NASDAQ: PLMR) is a specialty insurance holding company focused on providing medical stop-loss coverage and related administrative services to self-funded employer health plans in the United States. The firm operates through two primary business segments—Medical Stop-Loss and Specialty Program Management—to deliver tailored risk protection and comprehensive program administration.

In its Medical Stop-Loss segment, Palomar underwrites excess and aggregate stop-loss policies designed to shield self-insured employers from catastrophic medical claims that exceed pre-determined retention levels.